<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02926976</url>
  </required_header>
  <id_info>
    <org_study_id>The optimal treatment for TRS</org_study_id>
    <nct_id>NCT02926976</nct_id>
  </id_info>
  <brief_title>The Optimal Treatment for Treatment-resistant Schizophrenia</brief_title>
  <official_title>The Optimal Treatment for Treatment-resistant Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Mental Health Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Optimal Treatment for Treatment-resistant Schizophrenia
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To explore the curative effect and safety of Risperidone，aripiprazole，sodium
      valproate，modified electroconvulsive therapy(MECT), or Magnetic seizure therapy(MST) with
      Clozapine in the treatment of treatment-resistant schizophrenia， and to provide the basis for
      clinical medication.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Positive and Negative Syndrome Scale [PANSS]</measure>
    <time_frame>At baseline, 4th week, 8th week,12th week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in clinical global impression [CGI]</measure>
    <time_frame>At baseline, 4th week, 8th week,12th week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Simpson-Angus Scale [SAS]</measure>
    <time_frame>At baseline, 4th week, 8th week,12th week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Abnormal Involuntary Movement Scale[AIMS]</measure>
    <time_frame>At baseline, 4th week, 8th week,12th week</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>risperidone with clozapine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>risperidone, dosage form: 1 mg, dosage and frequency:3.0~6.0 mg/d; clozapine, dosage and frequency:300~600 mg/d; duration: 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>aripiprazole with clozapine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>aripiprazole, dosage form: 5 mg, dosage and frequency:15~30 mg/day; clozapine, dosage and frequency:300~600 mg/d; duration: 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sodium valproate with clozapine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>sodium valproate, dosage form: 250 mg, dosage and frequency:600~1200 mg/day; clozapine, dosage and frequency:300~600 mg/d; duration: 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>clozapine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>only clozapine, dosage and frequency:300~600 mg/d;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Modified electroconvulsive therapy with clozapine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 times MECT for 4 weeks, if the PANSS reductive ratio is less 20% in the end of 8th week by the using of risperidone with clozapine, aripiprazole with clozapine, sodium valproate with clozapine, or clozapine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Magnetic seizure therapy with clozapine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 times MST for 4 weeks, if the PANSS reductive ratio is less 20% in the end of 8th week by the using of risperidone with clozapine, aripiprazole with clozapine, sodium valproate with clozapine, or clozapine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidone with Clozapine</intervention_name>
    <description>Risperidone may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia</description>
    <arm_group_label>risperidone with clozapine</arm_group_label>
    <other_name>Risperidone Tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole with Clozapine</intervention_name>
    <description>Aripiprazole may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia</description>
    <arm_group_label>aripiprazole with clozapine</arm_group_label>
    <other_name>Aripiprazole Tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sodium valproate with Clozapine</intervention_name>
    <description>sodium valproate may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia</description>
    <arm_group_label>sodium valproate with clozapine</arm_group_label>
    <other_name>Valproate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>modified electroconvulsive therapy(MECT) with Clozapine</intervention_name>
    <description>modified electroconvulsive therapy(MECT) may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia</description>
    <arm_group_label>Modified electroconvulsive therapy with clozapine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Magnetic seizure therapy(MST) with Clozapine</intervention_name>
    <description>Magnetic seizure therapy(MST) may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia</description>
    <arm_group_label>Magnetic seizure therapy with clozapine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>clozapine</intervention_name>
    <description>clozapine may be used in the treatment of treatment-resistant schizophrenia</description>
    <arm_group_label>clozapine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The diagnosis of schizophrenia according to DSM-V

          -  18～60 years old

          -  2 prior failed treatment trials with 2 different antipsychotics at doses of at least
             600 mg/day chlorpromazine equivalents, each of at least 6 weeks duration;

          -  Signed an informed consent

        Exclusion Criteria:

          -  patients to be diagnosed according to DSM-V for substance abused, development delayed

          -  suffering from serious physical disease and can not accept the treatment

          -  MST contraindications: intracranial metal substance, with heart pacemakers and
             cochlear implants, intracranial pressure

          -  allergic to risperidone ,aripiprazole, or sodium valproate

          -  Participated in any clinical subject within 30 days

          -  Pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dengtang Liu</last_name>
    <phone>+86 21 64387250-73775</phone>
    <email>erliu110@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>DTliu</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>DT Liu, PHD</last_name>
      <email>erliu110@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2016</study_first_submitted>
  <study_first_submitted_qc>October 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2016</study_first_posted>
  <last_update_submitted>February 22, 2018</last_update_submitted>
  <last_update_submitted_qc>February 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Clozapine</mesh_term>
    <mesh_term>Aripiprazole</mesh_term>
    <mesh_term>Valproic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

